These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19944097)

  • 1. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.
    Koob AO; Ubhi K; Paulsson JF; Kelly J; Rockenstein E; Mante M; Adame A; Masliah E
    Exp Neurol; 2010 Feb; 221(2):267-74. PubMed ID: 19944097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.
    Bar-On P; Crews L; Koob AO; Mizuno H; Adame A; Spencer B; Masliah E
    J Neurochem; 2008 Jun; 105(5):1656-67. PubMed ID: 18248604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
    Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
    PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases.
    Spencer B; Potkar R; Trejo M; Rockenstein E; Patrick C; Gindi R; Adame A; Wyss-Coray T; Masliah E
    J Neurosci; 2009 Oct; 29(43):13578-88. PubMed ID: 19864570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease.
    Reyes JF; Ekmark-Léwen S; Perdiki M; Klingstedt T; Hoffmann A; Wiechec E; Nilsson P; Nilsson KPR; Alafuzoff I; Ingelsson M; Hallbeck M
    Acta Neuropathol Commun; 2021 Mar; 9(1):46. PubMed ID: 33743820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB.
    Yan R; Zhang J; Park HJ; Park ES; Oh S; Zheng H; Junn E; Voronkov M; Stock JB; Mouradian MM
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E12053-E12062. PubMed ID: 30509990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
    Zhou W; Milder JB; Freed CR
    J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.
    Games D; Seubert P; Rockenstein E; Patrick C; Trejo M; Ubhi K; Ettle B; Ghassemiam M; Barbour R; Schenk D; Nuber S; Masliah E
    Am J Pathol; 2013 Mar; 182(3):940-53. PubMed ID: 23313024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
    Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
    Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
    Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
    J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Dutta AK; Armstrong C; Luo D; Das B; Spencer B; Rissman RA
    ACS Chem Neurosci; 2023 Mar; 14(5):885-896. PubMed ID: 36749600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.
    Ubhi K; Inglis C; Mante M; Patrick C; Adame A; Spencer B; Rockenstein E; May V; Winkler J; Masliah E
    Exp Neurol; 2012 Apr; 234(2):405-16. PubMed ID: 22281106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.